At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 177 enrolled
Drug / intervention
Acalabrutinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Open Label, Randomized Study of the Efficacy and Safety of Acalabrutinib With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19
In Brief
A Phase 2 clinical trial evaluating Acalabrutinib for COVID-19. Completed, enrolled 177 participants across 50 sites in 14 countries.
Detailed Summary
CALAVI will investigate the safety, efficacy and pharmacokinetics of acalabrutinib together with Best Supportive Care in the treatment of COVID-19.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19
CountriesArgentina, Brazil, Chile, France, Germany, India, Italy, Japan, Mexico, Peru, Poland, Russia, South Africa, Turkey (Türkiye)
CollaboratorsAcerta Pharma BV
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedApr 2020
Enrollment StartJun 2020
Primary CompletionNov 2020
TodayJul 2026
First PostedApr 15, 2020
Enrollment StartJun 12, 2020
Primary CompletionNov 17, 2020
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 6.2 years ago
Interventions
Acalabrutinibdrug
Acalabrutinib- administered orally